Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Onconetix, Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on men's health and oncology diagnostics. Registration statements, amendments, proxy materials, and current reports describe securities offerings, preferred stock and warrant terms, common-stock structure, shareholder voting matters, and reverse-stock-split authorizations.
The company's SEC reports also disclose governance changes, board and executive appointments, material agreements, operating and financial results, clinical or regulatory matters, and risk factors related to its commercial-stage biotechnology business and Proclarix prostate cancer diagnostic.
Onconetix, Inc. director Sammy Dorf filed an initial ownership report on Form 3. This filing establishes his status as a director and brings his equity position under Section 16 reporting, but it does not list any transactions, purchases, or sales of Onconetix stock.
Onconetix, Inc. has implemented a 1-for-5 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 25, 2026. The company’s shares continue to trade on The Nasdaq Capital Market under the symbol ONCO with a new CUSIP number 68237Q 302.
Every five issued and outstanding shares of common stock were automatically converted into one share, with no change to the par value and no reduction in the number of authorized shares. The reverse split reduced the number of issued and outstanding shares from 3,464,686 to 692,927 and is intended to help the company maintain compliance with Nasdaq’s $1.00 minimum bid price requirement.
No fractional shares were issued; instead, stockholders entitled to a fractional share receive cash based on the closing sale price on March 24, 2026, adjusted for the split. Proportional adjustments were also made to equity awards, convertible preferred stock, and warrants.
Onconetix highlights Realbotix participation in Ericsson’s live pre-standard 6G over-the-air trial and reiterates its pending acquisition of Realbotix LLC. A Realbotix humanoid robot served as a live connected endpoint transmitting video and interacting in real time over Ericsson’s test network. Onconetix entered a definitive share exchange agreement to acquire 100% of Realbotix LLC in an all-stock transaction; closing is anticipated in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.
Onconetix, Inc. filed an amended report to add the employment agreement for its new Chief Executive Officer, David White, as an exhibit. The amendment does not change any prior disclosures.
The Board appointed Mr. White as CEO effective March 18, 2026, under an employment agreement providing a monthly base salary of $21,700 and customary non-compete, confidentiality and non-solicitation covenants. In connection with his appointment, monthly compensation was reduced by $5,000 for interim CFO Karina Fedasz and by $26,000 for Lead Independent Director Andrew Oakley.
Separately, director Timothy Ramdeen resigned from the Board and its key committees on March 19, 2026, with the company stating his departure was not due to any disagreement over operations or policies. The Board appointed Sammy Dorf as a new director and member of the Audit Committee, adding capital-markets and governance experience.
Onconetix, Inc. appointed David White as Chief Executive Officer effective March 18, 2026, formalizing leadership after an interim period. White brings more than 30 years of executive and board experience across transportation, healthcare, and manufacturing, including prior CEO, CFO, and COO roles and multiple public company directorships.
Under his employment agreement, White will receive a monthly base salary of $21,700 and is subject to non-compete, confidentiality, and non-solicitation covenants. In connection with his appointment, monthly compensation was reduced by $5,000 for Interim CFO Karina Fedasz and by $26,000 for Lead Independent Director Andrew Oakley, effective March 18, 2026.
Separately, director Timothy Ramdeen resigned from the Board and its key committees on March 19, 2026, with the company stating his departure was not due to any disagreement with management or the Board. The Board appointed entrepreneur and investor Sammy Dorf as a new director and Audit Committee member, adding capital markets and governance experience. Both White and Dorf are described as independent, with no family relationships or related-party transactions requiring disclosure.
Onconetix, Inc. is seeking stockholder approval at a Special Meeting on April 30, 2026 to authorize the Board to implement one or more reverse stock splits at ratios between 1-for-2 and 1-for-10 (aggregate up to 1-for-100) and to approve an adjournment power.
The Board unanimously recommends a FOR vote. The Record Date for voting is March 13, 2026, and 3,473,352 shares of Common Stock were outstanding as of that date. The proposal would let the Board decide timing and the final ratio, and any Reverse Stock Split would become effective upon filing an amendment with Delaware.
Onconetix, Inc. filed its annual report describing a pivot to men’s health diagnostics centered on Proclarix, a blood test for clinically significant prostate cancer, while warning of serious liquidity pressure. Proclarix generated only $23,091 of revenue in 2025, so the business remains early-stage and loss‑making.
As of December 31, 2025, Onconetix reported cash of $5.2 million, a working capital deficit of about $3.1 million, an accumulated deficit of roughly $131.2 million, and operating cash use of about $9.7 million in 2025; cash was $3.6 million as of March 11, 2026. Management concludes these factors raise substantial doubt about the company’s ability to continue as a going concern.
The company abandoned commercialization of ENTADFI, fully impaired those assets, settled about $8.8 million of related Veru notes through a mix of cash and securities, and now relies on external financing. A Share Exchange Agreement with Realbotix could transfer 75–90% of fully diluted equity to the seller, depending on Net Cash at closing, and requires at least $12.5 million of Net Cash plus a committed $125.0 million equity line. Onconetix previously regained Nasdaq compliance through a 1‑for‑85 reverse stock split and is under panel monitoring until July 7, 2026.
Onconetix, Inc. has signed a Share Exchange Agreement to acquire Realbotix, LLC in an all-stock transaction. Onconetix will issue new common shares so that the seller will own between 75% and 90% of the fully diluted shares, depending on Onconetix’s closing Net Cash level between $12.5 million and $20.0 million or more. Closing requires at least $12.5 million of Net Cash, a stockholder-approved S-4 registration and proxy process, Nasdaq listing compliance, and an equity line agreement for up to $125.0 million of Onconetix common stock. After closing, the combined company’s board will have five directors, four designated by Realbotix, and Realbotix’s management team will remain in place. Realbotix develops AI-powered humanoid robots for customer service, hospitality, healthcare and other applications, with multilingual and advanced vision capabilities.
Onconetix, Inc. is entering a definitive all‑stock share exchange to acquire 100% of Realbotix LLC, a U.S.-based AI-powered humanoid robotics company. At closing, Realbotix’s seller is expected to own between 75% and 90% of Onconetix’s fully diluted shares, depending on Onconetix’s Net Cash at closing. Ownership steps down from 90% to 75% as Net Cash increases from $12.5 million to at least $20 million. Closing conditions include a minimum $12.5 million Net Cash balance, an equity line agreement for up to $125 million of common stock purchases, conversion or amendment of Onconetix preferred and other convertible securities, shareholder approval, a fairness opinion, and required regulatory consents. After closing, Realbotix’s management team remains in place and four of five board seats will be designated by Realbotix. The combined company is expected to trade on Nasdaq and shift focus toward Realbotix’s AI-powered humanoid robotics business.
Onconetix, Inc. reported results from a special stockholder meeting held on February 3, 2026. Stockholders approved a reverse stock split proposal, with 562,803 votes for, 123,144 against, and 986 abstentions. They also approved an adjournment proposal, with 567,357 votes for, 118,604 against, and 972 abstentions.
The votes were cast based on 1,555,015 shares of common stock outstanding as of December 12, 2025, the record date for the meeting.